Addex Therapeutics Ltd
Research Addex Therapeutics Ltd (ADXN) on Bullrun: market cap USD 4.94M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerADXN
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 4.94M
- Financial periodQ1 2026
- RevenueCHF 0
- Net income-CHF 1.71M
- Free cash flow-CHF 765.84K
Valuation Snapshot
latest market cap is USD 4.94M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CHF 29.97K | -CHF 6.73M | -CHF 2.17M | n/a | n/a | CHF 1.64M | CHF 34.69K | CHF 4.77M |
| FY2024 | CHF 404.10K | CHF 7.06M | -CHF 5.37M | n/a | 18 | CHF 3.34M | CHF 41.99K | CHF 9.68M |
| FY2023 | n/a | n/a | n/a | n/a | -30 | CHF 3.87M | CHF 344.34K | CHF 1.15M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.94M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.51M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 5.74M | 3.5 | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.00M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 8.10M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 39.73M | n/a | n/a | n/a |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Addex Therapeutics Ltd's market cap?
Addex Therapeutics Ltd's market capitalization is USD 4.94M.
What does Addex Therapeutics Ltd do?
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder.